Physician profile
John D Mccarley
NPI 1760480321
$1,846.61
in general payments reported to CMS, 2019-2025
27 companies · $105 in 2025
The $105 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $634 · 2020: $95.14 · 2021: $118 · 2022: $407 · 2023: $205 · 2024: $282 · 2025: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $567 · Education: $25.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $566.95 |
| Education | $25.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $265.74 | 2019-2024 | Jynarque |
| Travere Therapeutics, INC. | $239.46 | 2023-2025 | Filspari |
| Vifor Pharma, INC. | $199.30 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $162.33 | 2019-2024 | Farxiga |
| Aurinia Pharma U.S., INC. | $130.78 | 2021-2024 | Lupkynis |
| Amgen INC. | $123.05 | 2019-2025 | Tavneos |
| Alexion Pharmaceuticals, INC. | $98.80 | 2019-2023 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $86.13 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $80.22 | 2021-2023 | Acthar |
| Janssen Pharmaceuticals, INC | $44.67 | 2019 | |
| Mallinckrodt Enterprises LLC | $44.48 | 2019 | |
| Opko Pharmaceuticals, LLC | $39.88 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $37.53 | 2022 | |
| Glaxosmithkline, LLC. | $36.00 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $35.54 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $33.22 | 2020-2022 | |
| Horizon Therapeutics Plc | $28.03 | 2019-2023 | Krystexxa |
| Scpharmaceuticals INC. | $23.96 | 2025 | |
| Genzyme Corporation | $20.95 | 2024 | |
| Akebia Therapeutics INC | $20.28 | 2019 | |
| Lundbeck LLC | $20.11 | 2019 | |
| Alnylam Pharmaceuticals INC. | $14.21 | 2022 | |
| Shire North American Group INC | $13.71 | 2019 | |
| Shield Therapeutics INC | $13.28 | 2023 | Accrufer |
| Kyowa Kirin, INC. | $12.71 | 2023 | |
| Amag Pharmaceuticals, INC. | $11.23 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mccarley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.